Pharmaceutical manufacturers of Paclitaxel

Fresenius Kabi operates as an international healthcare organization specializing in essential medications and advanced technologies for intravenous therapy, blood transfusion, and medical nourishment. The company's portfolio is instrumental in supporting the needs of severely and persistently unwell individuals. Additionally, it provides a variety of active pharmaceutical ingredients (APIs) and finalized goods fabricated within its own establishments

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.

SK pharmteco specializes in the production and manufacture of APIs, Advanced Intermediates, Registered Starting Materials and Key Building Blocks for commercial and clinical purposes. Our services encompass process R&D, development of analytical methods and stability, scale-up and optimization, validation, and commercial production of small molecules, along with extensive work on Adeno-Associated Virus (AAV) and Lentiviral vectors.

Headquartered in Chandigarh, India, Ind-Swift Laboratories Ltd. today is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration). With regulated 6+ manufacturing sites (including 2 group subsidiaries) in Punjab and Jammu, we cater to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. Today, Ind-Swift Laboratories Ltd. is a significant player in manufacturing APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. We also hold global leadership positions in the Macrolide Antibiotic segment.

Fresenius is an international healthcare conglomerate offering products and services for kidney dialysis, hospital care, and home medical treatment. The Fresenius Group comprises four distinct business segments - Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed - each managing its own global operations.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

Pfizer CentreOne® is a completely distinct global contract development and manufacturing organization (CDMO), as well as a prominent provider of specialty APIs and intermediates. Supported by resources from Pfizer, we have provided technical knowledge, regulatory assistance, and long-term supply for more than 40 years. With a network of over 35 sites spanning six continents, we are capable of securely and effectively guiding complex compounds from development to commercial manufacture. For more details, please visit http://www.pfizercentreone.com

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

We are a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.

Formed through the fusion of Farmabios, Novasep, and PharmaZell, Axplora stands out as a principal manufacturer of active pharmaceutical ingredients (APIs), ensuring the timely and scalable delivery of high-quality compounds. With a collective proficiency and a diverse production capacity spanning 9 industrial facilities, incorporating specialized technologies such as Hazardous Chemistry, Chromatography, ADCs, Steroids, Continuous Processes, Lipids, and HPAPIs, Axplora provides dependable and flexible solutions: CDMO services for small molecule APIs and biopharmaceuticals to both innovators and generic API Products. We, at Axplora, are committed to unifying Farmabios, Novasep, and PharmaZell, establishing ourselves as a top-tier API manufacturer dedicated to serving the foremost patient-focused pharmaceutical and biotechnology enterprises, ensuring the reliable and sustainable production of premium active ingredients in adherence to the highest industry standards. Axplora's mission is centered on empowering pharmaceutical companies to enhance the development of vital medications, fostering a faster, safer, and more dependable approach to benefit patients worldwide. Leveraging our combined expertise and manufacturing facilities spread across nine sites in Europe and India, along with a research and development center in the USA, Axplora is positioned to offer comprehensive CDMO solutions.

Alchem International, established in 1935, is an innovator in phytochemicals, offering plant-derived active pharmaceutical ingredients to the pharmaceutical, cosmetic, and nutraceutical industries. With over 75 years of expertise, Alchem has created a worldwide presence, marketing its products in more than 35 countries. Alchem owns three manufacturing sites spanning 62 acres in India and four international divisions with offices in India, Europe, Hong Kong, and the US. Alchem operates two segments – Phytoceuticals and EpiQue – that supply healthcare and cosmetic products to the Indian market and employs over 1,000 individuals globally.

With a history spanning more than 85 years in parenteral products, Baxter’s BioPharma Solutions (BPS) division collaborates with pharmaceutical firms to assist in achieving their commercialization goals for their drugs. BPS stands as a prominent contract manufacturing organization (CMO) that specializes in the production of specialized sterile injectables, aiming to address both traditional and complex sterile challenges. The state-of-the-art facilities, which have received awards, are situated in different primary locations. The Bloomington, Indiana, USA facility is renowned for its expertise in sterile contract manufacturing and offers form/fill/finish services and solutions for injectables tailored to meet conventional sterile manufacturing challenges. On the other hand, the Halle/Westfalen, Germany facility has over six decades of experience and is acknowledged as a top-tier manufacturer of oncology products and other sophisticated compounds. BPS is well-equipped to cater to pharmaceutical requirements with a wide range of capabilities for sterile fill/finish production, and its reputation is established on delivering high-quality products in a cGMP environment to its clients. The division offers delivery systems such as prefilled syringes, liquid/lyophilized vials, diluents for reconstitution, powder-filled vials, and sterile crystallization. Additionally, BPS covers diverse drug categories including small molecules, biologics, vaccines, cytotoxics, highly potent compounds, and antibody-drug conjugates (ADCs). From the initial formulation and development stages to the commercial launch, BPS provides comprehensive and tailored support services to navigate the complexities of the market and assist in maximizing the potential value of the drug molecule. Whether encountering formulation challenges, clinical supply obstacles, fluctuations in market demands, concerns regarding risk mitigation, or challenges related to patent expiry, BPS offers adaptable and customized solutions to aid in achieving commercialization objectives.

Mac-Chem has a National and Global footprint with a wide presence across the globe. Mac-Chem has carved a niche for itself in the exceedingly competitive and quality conscious sphere of Active Pharmaceutical Ingredients (API) manufacturing with US-FDA, EDQM, COFEPRIS, ANVISA, MFDS-Korea, WHO-GMP and ISO certified facilities

Products and Services ScinoPharm delivers high-value solutions to its customers with speed and flexibility through a full range of services from API development to commercialization, in addition to cGMP manufacture of materials for clinical trials. Our success is built on the growing partnerships with customers around the world in supply of generic APIs, custom process research services and custom manufacturing services.

Haorui, established in the year 1997, operates as a manufacturer and provider of APIs, pharmaceutical intermediates, veterinary products, and food additives. Furthermore, it aids international pharmaceutical firms in achieving domestic registration for their finished dosage forms to support their global expansion efforts. The company's array of USFDA approved products includes Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, and Dasatinib Monohydrate among others. Its headquarters is situated in Shenzhen, China, while it maintains four manufacturing sites in Hubei, Zhejiang, Jiangxi, and Henan. The Hubei facility is recognized for its USFDA and EU GMP approvals, specializing in the production of high potency and oncology materials within a dedicated oncology workshop, meeting OEB 5 material production standards. Haorui prides itself as a dependable partner for all your pharmaceutical needs.

Established in 2004, Murli Krishna Pharma Pvt Ltd is a youthful and dynamic organization specializing in Novel Drug Delivery Systems (NDDS). It offers a variety of effective solutions for enhancing the delivery of pharmaceutical products. The current operations involve the production of pre-finished formulations such as Pellets, Granules, and MUPS using Aqueous Based technology, Nano Particles, and Transdermal Oil. The facility is furnished with state-of-the-art machinery and 21 CFR, part 11 compliant instruments.

YungShin commenced its operations in 1952 and by 1978, it had also formed global subsidiaries such as Yung Zip Chemical in Taiwan, CTI in the US, YSP Southeast Asia, and YSP China. YungShin specializes in the development and manufacturing of finished products and APIs. The company also maintains stringent adherence to advanced ERP system, SAP, SOPs, and meticulous compliance with PIC/S GMP, Japanese MHLW, and US FDA regulations. YungShin offers comprehensive drug development and contract manufacturing services from its facilities in Taiwan.